To order this 250+ page report, which features 140+ figuresand 170+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key Market Insights
§ More than 65 industryplayers across the world are presently engaged in evaluating the clinicalapplications of over180 cannabinoid-derivatives that target the humanendocannabinoid signaling system
§ The pipeline featuresa variety of marketed / clinical stage therapies, being investigated for a widerange of target disease indications and designed for administration viadifferent routes
§ The geographicallandscape of this industry is likely to evolve in the next few years as federalauthorities legalize the use of medical cannabis across multiple countries
§ Despite theassociated stigma, many organizations have extended financial support to aidresearch efforts in this domain; the focus is on understanding the clinicalbenefits of endocannabinoid signaling in different diseases
§ The growing interestin this field is also reflected by the 170+ partnerships that have been signedin the last five years, involving both international and indigenousstakeholders, across different geographical marketplaces
§ Presently, NorthAmerican companies seem to be consolidating their presence indigenously, mostlythrough strategic acquisitions; key value drivers behind such deals includeproduct and geographical expansion
§ Future market size,based on revenue generation potential of marketed and late stage therapies, isanticipated to be distributed across a variety of therapeutic areas, targetreceptors and key geographical regions
For more information, please visit “EndocannabinoidSystem Targeted Therapeutics Market, 2020-2030.“
Contact Details
GauravChaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
